4//SEC Filing
Duker Jay S. 4
Accession 0001562180-25-001133
CIK 0001314102other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 6:19 PM ET
Size
10.2 KB
Accession
0001562180-25-001133
Insider Transaction Report
Form 4
Duker Jay S.
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
2025-02-09$6.50/sh−2,055$13,347→ 77,651 total - Exercise/Conversion
Restricted Stock Units
2025-02-09−7,000→ 0 totalExercise: $0.00→ Common Stock (7,000 underlying) - Exercise/Conversion
Common Stock
2025-02-09+7,000→ 79,706 total
Holdings
- 22,500(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
- [F2]These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F3]The restricted stock units vests in three annual installments beginning February 9, 2023.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001630864
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 6:19 PM ET
- Size
- 10.2 KB